ERBB2 and breast cancer: In conclusion, this first part of our study provided a comprehensive view of how proteomic and metabolic alterations contribute to pathogenesis in HER2-positive breast cancer and highlighted the role of oncogenic pathways such as PI3K-AKT-mTOR, which is frequently activated in this subtype.